Activation of HCV-specific T cells
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 23, 2007
Grant Date -
Sep 11, 2003
app pub date -
Feb 3, 2003
filing date -
Oct 27, 1999
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4.sup.+ and CD8.sup.+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully